UNASSIGNED: After decades of indolent progression, @entity731 may cause unheralded events, such as @entity583 , @entity1187 and @entity64 due to sudden @entity397 of @entity731 , and pharmacologically modulating plaque stability would reduce the risk of @entity65 . @entity1642 ( @entity1642 ) is responsible for the vulnerability of plaques. However, the underlying mechanism has not been fully elucidated. In this work, @entity6970 (-/-) @entity19 underwent perivascular carotid collar placement surgeries or sham operations were given higher (3.0mg/kg) and lower (0.3mg/kg) doses of @entity2425 (TM), and plaque stability was evaluated. It was shown that lower TM-treated animals exhibited @entity39 as well as fibrous cap thickness accompanied by a lower percentage of infiltrates and foam cells than the sham-operated and higher TM treated animals. Lower TM had a profound inhibitory effect on plasma inflammatory response and lipid profile in atherosclerotic @entity6970 (-/-) @entity19 . In addition, we found that the @entity6970 (-/-) @entity19 presented higher autophagy activity in response to lower TM administration while apoptosis was reduced. An in vitro study in @entity19 macrophages revealed that lower TM could markedly reduce lipid uptake and accumulation and cell apoptosis while significantly upregulated the expression of @entity30527 . However, higher TM had adverse effects. Finally, mild induction of @entity1642 by lower TM inhibits AKT-TSC- @entity3470 cascades to increase cellular autophagy. However, high TM failed to enhance autophagy and equilibrate elevated @entity13841 -mediated cell death in spite of the inhibition of AKT-TSC- @entity3470 signaling. In conclusion, lower TM stabilized plaques by activating autophagy through AKT-TSC- @entity3470 signaling.

Low dose XXXX enhances @entity731 stability by inducing autophagy.

@entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndrome'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity6970 :: ('11816(Tax:10090)', 'Gene') :: ['ApoE'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity30527 :: ('74244(Tax:10090)', 'Gene') :: ['Atg7'] @entity39 :: ('MESH:D009336', 'Disease') :: ['reduced plaque areas and necrotic cores'] @entity19 :: ('10090', 'Species') :: ['mice', 'murine'] @entity2425 :: ('MESH:D014415', 'Chemical') :: ['tunicamycin'] @entity13841 :: ('13198(Tax:10090)', 'Gene') :: ['CHOP'] @entity3470 :: ('21977(Tax:10090)', 'Gene') :: ['mTOR'] @entity397 :: ('MESH:D012421', 'Disease') :: ['rupture'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis', 'atherosclerotic plaques'] @entity1642 :: ('MESH:D015775', 'Disease') :: ['Endoplasmic reticulum stress', 'ERS'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases']
@entity2425 :: (MESH:D014415,Chemical) :: ['tunicamycin']
